Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-29,800
Closed -$1.98M 3035
2025
Q4
$1.98M Sell
29,800
-14,400
-33% -$931K ﹤0.01% 1873
2025
Q3
$2.97M Sell
44,200
-40,600
-48% -$3.21M ﹤0.01% 1622
2025
Q2
$7.4M Buy
84,800
+22,100
+35% +$1.73M 0.01% 1104
2025
Q1
$4.28M Buy
62,700
+40,700
+185% +$3.32M 0.01% 1325
2024
Q4
$1.71M Hold
22,000
﹤0.01% 1733
2024
Q3
$1.47M Buy
+22,000
New +$1.81M ﹤0.01% 1803
2023
Q2
Sell
-520,000
Closed -$60.4M 2391
2023
Q1
$60.4M Buy
520,000
+501,900
+2,773% +$56.2M 0.15% 170
2022
Q4
$2.05M Sell
18,100
-4,100
-18% -$450K 0.01% 1402
2022
Q3
$1.79M Sell
22,200
-3,800
-15% -$322K 0.01% 1549
2022
Q2
$1.94M Buy
+26,000
New +$2.37M 0.01% 1438
2018
Q4
Sell
-447,200
Closed -$15.5M 1475
2018
Q3
$15.5M Buy
+447,200
New +$13.9M 0.07% 358
2018
Q1
Sell
-624,800
Closed -$8.96M 2019
2017
Q4
$8.96M Buy
624,800
+544,800
+681% +$7.08M 0.03% 670
2017
Q3
$979K Buy
+80,000
New +$1.41M ﹤0.01% 1167

Other funds holding DXCM

Dmitry Balyasny's DXCM Position: Q2 2026 in Review

Dmitry Balyasny sold out of DexCom (DXCM) in Q2 2026, closing a stake of 566,312 shares — an estimated $35.6M sold.

Dmitry Balyasny first reported a position in DXCM in Q3 2015 and held it in 29 quarters. The position peaked at $113M in Q4 2022. 966 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Dmitry Balyasny reported no remaining DexCom position as of Q2 2026 after selling out during the quarter.
  • Dmitry Balyasny sold 566,312 DexCom shares in Q2 2026, an estimated $35.6M.
  • Dmitry Balyasny first reported a position in DexCom in Q3 2015 and held it in 29 quarters.
  • Dmitry Balyasny's DexCom position peaked at $113M in Q4 2022.
  • 966 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.